GARS1抗体—艾普蒂

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane 1-7: 293T,Jurkat,Raji and HT-29 cell，Mouse brain tissue，A431 and Hela cell lysates, Primary antibody: P02503(GARS1 Antibody) at dilution 1/800, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 60 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human prostate cancer tissue using P02503(GARS1 Antibody) at dilution 1/60. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human lung cancer tissue using P02503(GARS1 Antibody) at dilution 1/60. (Original magnification: ×200)    

  
  

The glycyl-tRNA synthetase 1 (GARS1) is a ubiquitously expressed enzyme that catalyzes the attachment of glycine to its cognate tRNA during protein synthesis. As a member of the aminoacyl-tRNA synthetase (ARS) family, GARS1 plays a critical role in maintaining translational fidelity. Mutations in the *GARS1* gene are linked to inherited peripheral neuropathies, notably Charcot-Marie-Tooth disease type 2D (CMT2D) and distal spinal muscular atrophy type V (dSMA-V), highlighting its importance in neuronal function. These mutations often disrupt enzymatic activity or protein interactions, leading to axonal degeneration and neuromuscular dysfunction.

GARS1 antibodies are tools used to study the enzyme's expression, localization, and pathogenic mechanisms in disease models. They aid in detecting GARS1 in tissues, cell lines, or patient samples, enabling research into genotype-phenotype correlations. Additionally, such antibodies help explore GARS1's non-canonical roles, including signaling pathways beyond translation. Challenges remain in distinguishing pathogenic mutants from wild-type GARS1 and understanding how specific mutations drive neuropathy. Research using these antibodies contributes to therapeutic development, including gene-targeted approaches or small-molecule interventions to restore GARS1 function in neurological disorders.